NCT03610971View on ClinicalTrials.gov

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

February 2, 2025

Study Completion Date

February 28, 2026

Conditions
Chronic Phase Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Interventions
DRUG

Ruxolitinib

Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).

DRUG

BCR-ABL Tyrosine Kinase Inhibitor (TKI)

The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.

Trial Locations (8)

10021

David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York

14263

Roswell Park Comprehensive Cancer Center, Buffalo

27710

Duke University Hospital, Durham

30322

Emory -Winship Cancer Institute, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

97239

Oregon Health & Science University, Portland

07645

Memorial Sloan Kettering - Bergen, Montvale

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

H. Jean Khoury Cure CML Consortium

OTHER

collaborator

Incyte Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER